<?xml version="1.0" encoding="UTF-8"?>
<p>The outbreak caused by SARS-CoV-2 is an unprecedented global public health threat owing to the high transmission rate of the virus, coupled with currently no drugs or vaccines approved. In the pandemic setting with rapid virus transmission, new vaccine production is of exceptional importance, besides much needed therapeutic, that are both expected to need months to years to develop. The rapid response action to the emergent pandemic is repurposing of approved antiviral, antimalarial, antiparasitic agents and those based on immunotherapy approaches to treat COVID-19, with some clinical trials already started [
 <xref rid="B4-molecules-25-03830" ref-type="bibr">4</xref>,
 <xref rid="B5-molecules-25-03830" ref-type="bibr">5</xref>,
 <xref rid="B6-molecules-25-03830" ref-type="bibr">6</xref>].
</p>
